Design, results of in vitro antimycobacterial evaluation, and study of structure-activity relationships of various pyrazinecarboxylic acid reversible derivatives are presented. This review deals with some pyrazinamide analogues/prodrugs derived from Nphenylpyrazine- 2-carboxamides (1), arylaminopyrazine-2,5-dicarbonitriles (2), aryl/alkylsulphanylpyrazines (3,4), and aroylpyrazines (5) effecting >50% inhibition in the primary antimycobacterial screen. The promising pyrazine candidates for further antimycobacterial evaluation were discovered. Results give good view onto structure-activity relationships of these analogues and promise even better activity of new compounds prepared after some structure optimization experiments.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Faculty of Pharmacy in Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12022207

003      

CZ-PrNML

005      

20160318082350.0

007      

ta

008      

120806s2011 ne f 000 0#eng||

009      

AR

024    7_

$a 10.2174/138161211798194477 $2 doi

035    __

$a (PubMed)22074423

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Doležal, Martin, $u Department of Pharmaceutical, Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic. martin.dolezal@faf.cuni.cz $7 jn19981000714 $d 1961-

245    10

$a Antimycobacterial evaluation of pyrazinoic acid reversible derivatives / $c Martin Dolezal, Diana Kesetovic, Jan Zitko

520    9_

$a Design, results of in vitro antimycobacterial evaluation, and study of structure-activity relationships of various pyrazinecarboxylic acid reversible derivatives are presented. This review deals with some pyrazinamide analogues/prodrugs derived from Nphenylpyrazine- 2-carboxamides (1), arylaminopyrazine-2,5-dicarbonitriles (2), aryl/alkylsulphanylpyrazines (3,4), and aroylpyrazines (5) effecting >50% inhibition in the primary antimycobacterial screen. The promising pyrazine candidates for further antimycobacterial evaluation were discovered. Results give good view onto structure-activity relationships of these analogues and promise even better activity of new compounds prepared after some structure optimization experiments.

650    _2

$a zvířata $7 D000818

650    _2

$a antibakteriální látky $x škodlivé účinky $x chemie $x farmakologie $7 D000900

650    _2

$a buněčné linie $7 D002460

650    _2

$a viabilita buněk $x účinky léků $7 D002470

650    _2

$a racionální návrh léčiv $7 D015195

650    _2

$a lidé $7 D006801

650    _2

$a mikrobiální testy citlivosti $7 D008826

650    _2

$a molekulární struktura $7 D015394

650    _2

$a Mycobacterium $x účinky léků $x růst a vývoj $7 D009161

650    _2

$a prekurzory léčiv $x škodlivé účinky $x chemie $x farmakologie $7 D011355

650    _2

$a pyrazinamid $x škodlivé účinky $x analogy a deriváty $x chemie $x farmakologie $7 D011718

650    _2

$a vztahy mezi strukturou a aktivitou $7 D013329

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Kesetovic, Diana $u Department of Pharmaceutical, Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic

700    1_

$a Zitko, Jan $u Department of Pharmaceutical, Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic $7 xx0230408

773    0_

$w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 17, č. 32 (2011), s. 3506-3514

856    41

$u https://pubmed.ncbi.nlm.nih.gov/22074423 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m $z 0

990    __

$a 20120806 $b ABA008

991    __

$a 20160318082412 $b ABA008

999    __

$a ok $b bmc $g 944120 $s 779504

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2011 $b 17 $c 32 $d 3506-3514 $i 1873-4286 $m Current pharmaceutical design $n Curr. Pharm. Des. $x MED00007893

GRA    __

$a NS10367 $p MZ0

LZP    __

$b NLK111 $a Pubmed-20120806/12/01